Analysis of Serum IgG1 to Predict Progression and Therapeutic Effect in Patients with Multiple Myeloma

Table 5

Proportion of immune cells in 57 patients with multiple myeloma compared with healthy controls.

	Healthy control	MM	value
CD3^+ (N = 57; range: 61.1–77%)	68.90 ± 4.58	68.93 ± 14.64	<0.99079
CD3^+CD4^+ (N = 57; range: 25.8–41.6%)	35.31 ± 4.58	28.95 ± 14.10	<0.02259
CD3^+CD8^+ (N = 57; range: 18.1–29.6%)	24.90 ± 3.25	38.82 ± 16.11	<0.001
CD4^+/CD8^+ (N = 57; range: 0.9–1.9)	1.41 ± 0.31	0.96 ± 0.74	<0.00290
CD3^−CD19^+ (N = 57; range: 7.3–18.2%)	11.04 ± 3.21	7.12 ± 8.15	<0.01654
CD16^+CD56^+ (N = 57; range: 8.1–25.6%)	13.53 ± 4.36	22.86 ± 13.95	<0.001